dc.contributor.author
Seeliger, Hendrik
dc.contributor.author
Pozios, Ioannis
dc.contributor.author
Assmann, Gerald
dc.contributor.author
Zhao, Yue
dc.contributor.author
Müller, Mario H.
dc.contributor.author
Knösel, Thomas
dc.contributor.author
Kreis, Martin E.
dc.contributor.author
Bruns, Christiane J.
dc.date.accessioned
2019-04-01T15:16:03Z
dc.date.available
2019-04-01T15:16:03Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/24255
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-2027
dc.description.abstract
Background: The relevance of estrogen receptor (ER) expression in pancreatic ductal adenocarcinoma (PDAC) is largely unknown. Clinical trials targeting ER with selective estrogen receptor modulators in pancreatic cancer did not show any benefit. Here, we analyze the impact of recently characterized ER isoform beta on survival in a cohort of patients with resected PDAC. Methods: Eighty-four patients having undergone pancreatic resection for PDAC at a single institution were identified. Tissue microarrays were constructed of archival tumor specimens. The expression of ER beta was determined by immunohistochemistry and quantified by a system established for estrogen receptor expression in breast cancer. ER beta expression was then correlated with clinicopathological parameters, and univariate and multivariate survival analyses were performed. Results: Nuclear expression of ER beta was found in 31% of tumors. No significant correlation was found between ER beta expression and TNM status, tumor grade, age or sex. Univariate analysis revealed nodal metastasis and the expression of ER beta as factors correlating with a shorter overall survival and disease free survival. When comparing ER beta expression in patients surviving more than 24months with those who died from the tumor within 12 or 24months, respectively, a significantly lower ER beta expression was found in the long term survivors. In multivariate analysis, ER beta expression was demonstrated to be an independent predictor of shorter overall survival. Conclusions: In resected PDAC, expression of ER beta seems to correlate with poor prognosis. These data may help to identify patients who may benefit from additional systemic therapy including selective estrogen receptor modulators.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
Pancreatic ductal adenocarcinoma
en
dc.subject
Pancreatic cancer
en
dc.subject
Estrogen receptor beta
en
dc.subject
Survival analysis
en
dc.subject
Tissue microarray
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Expression of estrogen receptor beta correlates with adverse prognosis in resected pancreatic adenocarcinoma
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
1049
dcterms.bibliographicCitation.doi
10.1186/s12885-018-4973-6
dcterms.bibliographicCitation.journaltitle
BMC Cancer
dcterms.bibliographicCitation.number
1
dcterms.bibliographicCitation.originalpublishername
BMC
dcterms.bibliographicCitation.volume
18
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
30373552
dcterms.isPartOf.issn
1471-2407